恩托塞替尼治疗惰性非霍奇金淋巴瘤和套细胞淋巴瘤的开放标签2期试验
这项多中心2期研究评估了口服选择性Syk抑制剂恩托塞替尼单药(800 mg每日两次)治疗复发或难治性惰性非霍奇金淋巴瘤或套细胞淋巴瘤的疗效。主要终点为套细胞淋巴瘤16周和无痛进展生存率63.9%(95%CI 45-77.8%),滤泡性淋巴瘤、淋巴浆细胞样淋巴瘤/华氏巨球蛋白血症和边缘区淋巴瘤24周无进展生存率分别为51.5%、69.8%和46.2%。恩托塞替尼单药活性有限,毒性可控。
要点
- 套细胞淋巴瘤队列16周无进展生存率为63.9%(95%CI 45-77.8%)。
- 滤泡性淋巴瘤24周无进展生存率为51.5%(95%CI 32.8-67.4%)。
- 恩托塞替尼单药活性有限,毒性可控。
核心结论
- 恩托塞替尼在这些患者人群中单药活性有限,毒性可控。
研究设计与样本
- 多中心、开放标签、2期研究,评估恩托塞替尼单药治疗复发或难治性惰性非霍奇金淋巴瘤或套细胞淋巴瘤。
- 受试者接受恩托塞替尼800 mg每日两次口服。
- 共评估41例滤泡性淋巴瘤、17例淋巴浆细胞样淋巴瘤/华氏巨球蛋白血症、17例边缘区淋巴瘤和39例套细胞淋巴瘤患者。
- 主要终点为套细胞淋巴瘤患者16周无进展生存率(定义为未出现进展或死亡)以及滤泡性淋巴瘤、淋巴浆细胞样淋巴瘤/华氏巨球蛋白血症和边缘区淋巴瘤患者24周无进展生存率。
主要发现
- 套细胞淋巴瘤队列16周无进展生存率为63.9%(95%CI 45-77.8%)。
- 滤泡性淋巴瘤队列24周无进展生存率为51.5%(95%CI 32.8-67.4%)。
- 淋巴浆细胞样淋巴瘤/华氏巨球蛋白血症队列24周无进展生存率为69.8%(95%CI 31.8-89.4%)。
- 套细胞淋巴瘤队列24周无进展生存率为56.6%(95%CI 37.5-71.8%)。
- 边缘区淋巴瘤队列24周无进展生存率为46.2%(95%CI 18.5-70.2%)。
关键数值与推荐
- 最常见治疗中出现的不良事件为疲乏、恶心、腹泻、呕吐、头痛和咳嗽。
- 常见实验室异常为贫血、中性粒细胞减少和血小板减少;天冬氨酸转氨酶、丙氨酸转氨酶、总胆红素和血清肌酐均升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spleen tyrosine kinase (Syk) mediates B-cell receptor signalling in normal and malignant B cells. Entospletinib is an oral, selective Syk inhibitor. Entospletinib monotherapy was evaluated in a multicentre, phase 2 study of patients with relapsed or refractory indolent non-Hodgkin lymphoma or mantle cell lymphoma (MCL). Subjects received 800 mg entospletinib twice daily. Forty-one follicular lymphoma (FL), 17 lymphoplasmacytoid lymphoma/Waldenström macroglobulinaemia (LPL/WM), 17 marginal zone lymphoma (MZL) and 39 MCL patients were evaluated. The primary endpoint was a progression-free survival (PFS) rate (defined as not experiencing progression or death) at 16 weeks for patients with MCL and at 24 weeks for patients with FL, LPL/WM and MZL. The most common treatment-emergent adverse events were fatigue, nausea, diarrhoea, vomiting, headache and cough. Common laboratory abnormalities were anaemia, neutropenia and thrombocytopenia; aspartate transaminase, alanine transaminase, total bilirubin and serum creatinine were all increased. PFS at 16 weeks in the MCL cohort was 63·9% [95% confidence interval (CI) 45-77·8%]; PFS at 24 weeks in the FL, LPL/WM, MCL and MZL cohorts was 51·5% (95% CI 32·8-67·4%), 69·8% (95% CI 31·8-89·4%), 56·6% (95% CI 37·5-71·8%) and 46·2% (95% CI 18·5-70·2%), respectively. Entospletinib had limited single-agent activity with manageable toxicity in these patient populations.
引用
- Andorsky DJ, Kolibaba KS, Assouline S, et al. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2018. PMID: 30183069. doi:10.1111/bjh.15552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。